- Home
- CALC vs ICMB Comparison
CALC vs ICMB Comparison
Compare CALC & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- ICMB
- Stock Information
- Founded
- CALC 2011
- ICMB 2012
- Country
- CALC United States
- ICMB United States
- Employees
- CALC N/A
- ICMB N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- ICMB Finance: Consumer Services
- Sector
- CALC Health Care
- ICMB Finance
- Exchange
- CALC Nasdaq
- ICMB Nasdaq
- Market Cap
- CALC 45.4M
- ICMB 40.8M
- IPO Year
- CALC N/A
- ICMB N/A
- Fundamental
- Price
- CALC $3.11
- ICMB $2.83
- Analyst Decision
- CALC Strong Buy
- ICMB
- Analyst Count
- CALC 2
- ICMB 0
- Target Price
- CALC $14.50
- ICMB N/A
- AVG Volume (30 Days)
- CALC 46.6K
- ICMB 29.4K
- Earning Date
- CALC 11-12-2025
- ICMB 11-13-2025
- Dividend Yield
- CALC N/A
- ICMB 17.67%
- EPS Growth
- CALC N/A
- ICMB N/A
- EPS
- CALC N/A
- ICMB 0.93
- Revenue
- CALC N/A
- ICMB $20,422,069.00
- Revenue This Year
- CALC N/A
- ICMB N/A
- Revenue Next Year
- CALC N/A
- ICMB N/A
- P/E Ratio
- CALC N/A
- ICMB $3.04
- Revenue Growth
- CALC N/A
- ICMB N/A
- 52 Week Low
- CALC $1.42
- ICMB $2.46
- 52 Week High
- CALC $5.65
- ICMB $3.47
- Technical
- Relative Strength Index (RSI)
- CALC 48.87
- ICMB 46.68
- Support Level
- CALC $3.04
- ICMB $2.81
- Resistance Level
- CALC $3.15
- ICMB $2.86
- Average True Range (ATR)
- CALC 0.18
- ICMB 0.08
- MACD
- CALC -0.03
- ICMB -0.01
- Stochastic Oscillator
- CALC 21.74
- ICMB 25.00
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.